Integrated preclinical to cGMP clinical manufacturing pipelines, designed to eliminate tech-transfer failure points between Phase 1 safety cohorts and pivotal Phase 3 trials.
Navigating the complex clinical transition from exploratory early-phase safety assessments to statistically powered multi-center therapeutic proof-of-concept (PoC) protocols.
Phase 2 clinical trials historically represent the highest attrition rate in biopharmaceutical and natural drug development (~68% failure rate). As an OEM/CDMO partner, our mission is to eliminate Chemistry, Manufacturing, and Controls (CMC) variability as an extraneous trial failure variable. Through robust analytical characterization, impurity profiling, and automated process control, we ensure that therapeutic biological signals are never obscured by formulation variance or active batch inconsistencies.
While Phase 2a explores preliminary efficacy and target engagement across narrow patient groups (50–100 subjects), Phase 2b necessitates strict dose-ranging regimens (100–300+ subjects) across multiple geographic clinical sites. Our OEM production lines accommodate flexible batch scaling—from 5 kg pilot campaigns up to multi-hundred-kilogram cGMP validation batches—guaranteeing rapid adaptation to expanding protocol amendments without regulatory re-filing delays.
Executing valid therapeutic evaluation requires impeccable Investigational Medicinal Product (IMP) blinding. Our automated pharmaceutical processing lines yield matching placebos with identical organoleptic profiles (color, texture, odor, dissolution rate, and specific gravity). This is vital for botanical derivatives and natural complex matrices, where distinctive aromas and bitter tasting notes demand advanced microencapsulation and masking technologies.
Biotechnology enterprises, clinical research organizations (CROs), and multinational sponsors require contract manufacturing organizations (CDMOs) that operate with global compliance fluency, agile speed, and cost efficiency.
Global procurement teams navigating the US FDA, EMA, or NMPA frameworks demand absolute data integrity under 21 CFR Part 11. Our end-to-end electronic batch records (eBR) track raw botanical origins, chemical markers, and critical process parameters (CPPs) through every production cycle.
A clinical manufacturer must deliver more than just physical drug product; they must deliver comprehensive regulatory dossiers. We generate complete IND/IMPD-compliant Module 3 CMC documentation, including validated analytical stability studies (accelerated and real-time ICH conditions).
Trial supplies require temperature-controlled secondary packaging, serialized labelling under Annex 13 requirements, and QP (Qualified Person) release facilitation. We coordinate multi-regional depot distribution for clinical sites spanning the US, Europe, and Asia-Pacific.
Speed to clinic is paramount. By deploying standardized single-use technologies (SUT) and pre-validated chromatographic skid platforms, our technical transfer timelines from benchtop validation to first-in-human or Phase 2 cGMP runs are compressed by up to 40%.
Combining advanced Process Analytical Technology (PAT), continuous multi-stage extraction, and domestic agricultural backward integration to insulate global sponsors from geopolitical and supply shocks.
Our Changsha smart manufacturing facility utilizes in-line NIR (Near-Infrared) sensors and automated high-pressure liquid chromatography monitoring. This continuous Process Analytical Technology automatically modulates temperature, solvent flow, and retention times in real time, locking critical active compound titers within ±1.5% batch tolerance.
Western clinical manufacturing facilities often face crippling operational overhead and multi-month queue backlogs. Leveraging Hunan's chemical synthesis and natural medicine industrial corridor, we offer sponsors a 45–60% reduction in pilot-scale API and finished dose manufacturing costs without compromising cGMP or ISO compliance.
For botanical pharmaceuticals, active variation begins at the soil level. We manage direct Good Agricultural and Collection Practices (GACP) supply nodes across China. Geographic origin, seasonal timing, soil heavy metal presence, and pesticide residuals are pre-screened, guaranteeing pristine botanical feedstock for downstream clinical extractions.
MedGence (Yineng Pharma) combines over 14 years of clinical development leadership, validated across hundreds of pharmaceutical manufacturers and Class 3A TCM hospitals.
Tailored delivery technologies engineered specifically for the chemical complexities and bioavailability demands of Phase 2 investigational products.
For small molecule candidates and phytocomplexes suffering from rapid first-pass metabolism or gastric instability, our formulation teams engineer matrix tablets, enteric-coated micropellets, and multi-particulate capsule systems. Our Phase 2 clinical lots guarantee uniform pharmacokinetic (PK) and pharmacodynamic (PD) profiles across diverse patient demographics.
Lipophilic active fractions, essential terpene extracts, and hydrophobic polyphenols demand specialized lipid-based drug delivery systems (SMEDDS/SEDDS). We formulate clear oral liquids, concentrated pastes, and microencapsulated softgel capsules designed to dramatically amplify cellular uptake and intestinal permeability.
Phase 2 dose-finding protocols require intricate packaging schemes (e.g., 25 mg vs. 50 mg vs. 100 mg vs. placebo). We execute cleanroom blister sealing, randomized clinical kit packaging, child-resistant tamper-evident bottling, and multilingual dynamic labeling configured for cross-border trial sites.
Our contract development and cGMP pilot manufacturing facilities serve national pharmaceutical champions, innovative biotechs, and prestigious clinical medical centers.
Tongrentang Group
CR Sanjiu Pharmaceutical
Sunflower Pharmaceutical
Livzon Pharma Group
Dihon Pharmaceutical
Golden Throat Group
Yangtzi River Pharma
Humanwell Healthcare
Shuguang Hospital (Shanghai)
Second Xiangya Hospital
First Hospital of Hunan TCM
Kangmei Pharmaceutical
Detailed answers for Chief Scientific Officers, VP of CMC, and Global Sourcing Heads evaluating Phase 2 contract manufacturing execution.
Select from our validated research and cGMP manufacturing modules to support your next clinical trial milestone.
Initiate technical discussions with our scientific steering committee. We provide comprehensive gap analysis for existing CMC packages, formulate custom dosage protocols, and schedule cGMP clinical batch production runs.
